CNS Pharmaceuticals Inc. CNSP Archives - Page 20 of 22

WednesdayDec 09, 2020 11:45 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Describes ‘Most Exciting Thing That I’ve Done’ on Gamechangers LIVE

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in…

TuesdayDec 08, 2020 2:14 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shines Spotlight on Clinical Design for Upcoming Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing a drug candidate it hopes will beat the deadly brain cancer Glioblastoma Multiforme (“GBM”). The company recently announced that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review and discussed a novel clinical design for its upcoming Phase 2 U.S. trial in a webinar open to the public. “I would like to remind everyone that this upcoming Phase 2…

TuesdayDec 01, 2020 2:36 pm

CNS Pharmaceuticals (NASDAQ: CNSP) Advances Brain Cancer Drug Candidate and Sponsors Annual SNO Conference

Biotechnology developer CNS Pharmaceuticals is preparing, with its partner WPD Pharmaceuticals, a global set of Phase 2 trials for its drug candidate Berubicin, which has shown promise in combating the effectively fatal glioblastoma multiforme (“GBM”) brain cancer Since another company conducted Phase 1 safety trials for Berubicin 14 years ago, one patient has survived cancer-free while two others saw reductions in tumor size of up to 80 percent The Phase 2 trials will build on the Phase 1 results, conducting targeted testing that offers side-by-side comparison between Berubicin and chemotherapy drug lomustine in real time beginning next year The company…

WednesdayNov 25, 2020 10:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) IND Application for Cancer Drug Berubicin Accepted for Review

CNS Pharmaceuticals wants to obtain FDA authorization for an Investigational New Drug application for drug candidate Berubicin, a novel treatment for Glioblastoma Multiforme Company believes it’s on track to start in Q1 2021 a potentially pivotal Phase II Berubicin trial with adult GBM patients who have failed their primary treatment for the disease Separately, a Phase II adult trial and a first-ever Phase I pediatric trial are slated to begin in 2021 in Poland in collaboration with sub-licensee partner, WPD Pharmaceuticals Members of CNS’s management team attended A.G.P.’s Virtual Health Symposium, meeting 1-on-1 with investors CNS Pharmaceuticals (NASDAQ: CNSP), a…

TuesdayNov 24, 2020 1:21 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Brain Cancer Drug During Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. During the broadcast, CNS Pharmaceuticals CEO John Climaco explains that the company has recently submitted an investigational new drug (“IND) application to the U.S. Food & Drug Administration (“FDA”) for its brain cancer drug, Berubicin. Climaco also discusses CNSP’s intent to begin Phase 2 trials of the drug during Q1 2021. The Phase 2 trial is designed to analyze the efficacy of Berubicin in treating patients with Glioblastoma…

ThursdayNov 19, 2020 2:11 pm

CNS Pharmaceuticals (NASDAQ: CNSP) Outlines Plans for Advancing Drug It Hopes Will Beat Deadly Brain Cancer

Biotechnology developer CNS Pharmaceuticals is working to advance the clinical trials of a novel brain cancer-fighting drug candidate with the aim of developing a new, effective therapy for treating an otherwise incurable disease The company plans a complex, multi-armed Phase 2 trial of its candidate Berubicin in hopes that the drug candidate may ultimately gain an expedited pathway to approval and registration from the FDA The trial for combatting Glioblastoma Multiforme is expected to begin next year, and on Nov. 12 the company’s officers launched a webinar to provide information on how the trial will be designed CNS Pharmaceuticals is…

ThursdayNov 19, 2020 10:42 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Joint Sponsor 2020 SNO Virtual Meeting

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, will be joint sponsoring the 2020 Society of NeuroOncology (“SNO”) Virtual Meeting. CNS will be sharing sponsorship with WPD Pharmaceuticals. The virtual event is slated for Nov. 19–21, 2020. The joint sponsorship includes a booth in the virtual exhibit hall and is categorized as a Supporter level. In addition, one of the panel discussions will feature a member of CNS’s Science Advisory Board; Dr. Patrick Wen will be part of the panel discussing clinical…

WednesdayNov 18, 2020 10:07 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in A.G.P. Healthcare Symposium

CNS Pharmaceuticals (NASDAQ: CNSP) management will be participating in A.G.P.’s upcoming Virtual Healthcare Symposium. The symposium is scheduled for Nov. 19, 2020. Leaders of CNSP, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, will be part of the event, which includes one-on-one virtual investor meetings. Potential investors who may want to attend the conference should contact an A.G.P. representative. CNS plans to start a Phase 2 clinical trial of its lead drug candidate Berubicin, which is designed to treat glioblastoma multiforme (“GBM”), an aggressive and incurable form of…

TuesdayNov 17, 2020 10:17 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Files IND Application for Berubicin in Treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for Berubicin in the treatment of Glioblastoma Multiforme (“GBM”). Pending the FDA's acceptance of the company's filing, CNS Pharmaceuticals plans to evaluate the efficacy of Berubicin in a Phase 2 Trial for adults with GBM who have failed first-line therapy and commence the trial within the first quarter of 2021. “Our laser focus from…

ThursdayNov 12, 2020 10:41 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosting Webcast for Discussion of Phase 2 Clinical Trial Design

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has scheduled a webcast today during which it will be discussing its plan to submit a phase 2 clinical trial design for FDA review. The call, which will be moderated by Robert LeBoyer, managing director of Equity Research at Ladenburg Thalmann & Co. Inc., will start at 4:30 p.m. ET. The phase 2 trial design is for the U.S. trial for CNSP’s Berubicin. Berubicin is the company’s lead drug candidate for the treatment of glioblastoma multiforme…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP